Clinical trials: Visual Fields
Epilepsies, Partial
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months.
- Trial name
- NCT00351611
- Testing
- Lyrica (pregabalin)
- Where
- 150 sites in United States, Bulgaria and 7 more
- Volunteers
- 187 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Visual Field Defect
Visual Field Analysis With Artificial Intelligence
The purpose of this study is to analyze visual field data from healthy participants. This data will be used to develop and optimize a new visual field perimeter test.
- Trial name
- VFAAI (NCT06920290)
- Testing
- Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sight Intelligence Engineering Corporation
Age Related Macular Degeneration, Choroidal Neovascularization
Sensitivity of the Home Macular Perimeter (HMP)
estimate the sensitivity of the HMP test in identifying visual field functional defects in subjects with CNV secondary to AMD
- Trial name
- HMP (NCT00604071)
- Where
- 10 sites in United States
- Volunteers
- 99 people
- Sponsor
- Notal Vision Ltd.
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447980
- Testing
- NT-501
- Where
- 12 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurotech Pharmaceuticals
Glaucoma, Primary Open Angle Glaucoma
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.
- Conditions
- Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
- Trial name
- TES-GPS (NCT06682962)
- Testing
- Transcorneal electrical stimulation (TES) with the OkuStim 2 System
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Okuvision GmbH
Hemianopsia, Homonymous
Testing of a Functional Outcome Measure for Those With Visual Field Defects
This study is designed in two Phases. In phase 1, the Functional Outcome Measure will be tested to determine its validity and reliability in three populations, subjects that have not had a stroke and have no visual field defect…
- Trial name
- FOM (NCT00731796)
- Testing
- Functional Outcome Measure
- Where
- 3 sites in United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- NovaVision, Inc.
Age Related Macular Degeneration
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The Foresee Home is used in the recent years to detect age-related macular degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT01073592
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Open Angle Glaucoma
TF for the Prediction of Visual Field Progression
Baseline 24-hour SENSIMED Triggerfish (TF) recordings as well as functional and structural vision tests measured prospectively every 3 months over a 2-year period, will be used to model TF's ability to serve as a risk factor for…
- Trial name
- NCT03047239
- Testing
- SENSIMED Triggerfish
- Sponsor
- Sensimed AG
Optic Nerve Disease, Macular Disease
Implementation of the NEDS EyeCTester App
Group 4a and 4b was an FDA trial that showed that patients who have an Amsler grid abnormality on paper, have a similar abnormality on the app.
- Conditions
- Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
- Trial name
- NCT04607369
- Testing
- EyeCTester
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neuro-Eye Diagnostic Systems, LLC